Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are of huge therapeutic benefit in the treatment of rheumatoid arthritis and various types of inflammatory conditions. The target for these drugs is cyclooxygenase (COX), a rate-limiting enzyme involved in the conversion of arachidonic acid into inflammatory prostaglandins. COX-2 selective inhibitors are believed to have the same anti-inflammatory, anti-pyretic and analgesic activities as that of nonselective inhibitor NSAIDs with little or none of the gastrointestinal side effects. Thus, in the last 6-7 years several selective COX-2 inhibitors including coxibs were discovered and introduced into clinic. Recent reports evidence that selective COX-2 inhibitor such as rofecoxib, can lead to thrombotic cardiovascular events through inhibition of prostacyclin formation in the infracted heart. This has resulted in withdrawal of rofecoxib from the clinic in September 2004. Moreover, the COX-2/COX-1 selectivity ratio is vital in the design of COX-2 inhibitory drugs, as it is clear from rofecoxib, which is more than 50-fold COX-2 selective. After looking at all above mentioned facts, natural product-based compounds seem better as these compounds are generally supposed to be devoid of severe side effects. The literature indicates that natural product-based compounds are mainly COX-1 selective. Through minor semisynthetic changes in the structures, their selectivity towards COX-2 can be increased. The present review article addresses natural product COX inhibitors of plant and marine origin, reported during last ten years and their advantages, possible leads for further development and current status. In addition we describe our experience in the characterization, design and synthesis of potential natural COX inhibitors.
Keywords: Anti-inflammatory, natural products, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2)
Current Medicinal Chemistry
Title: Cyclooxygenase Inhibitory Natural Products: Current Status
Volume: 13 Issue: 6
Author(s): Sanjay M. Jachak
Affiliation:
Keywords: Anti-inflammatory, natural products, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2)
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are of huge therapeutic benefit in the treatment of rheumatoid arthritis and various types of inflammatory conditions. The target for these drugs is cyclooxygenase (COX), a rate-limiting enzyme involved in the conversion of arachidonic acid into inflammatory prostaglandins. COX-2 selective inhibitors are believed to have the same anti-inflammatory, anti-pyretic and analgesic activities as that of nonselective inhibitor NSAIDs with little or none of the gastrointestinal side effects. Thus, in the last 6-7 years several selective COX-2 inhibitors including coxibs were discovered and introduced into clinic. Recent reports evidence that selective COX-2 inhibitor such as rofecoxib, can lead to thrombotic cardiovascular events through inhibition of prostacyclin formation in the infracted heart. This has resulted in withdrawal of rofecoxib from the clinic in September 2004. Moreover, the COX-2/COX-1 selectivity ratio is vital in the design of COX-2 inhibitory drugs, as it is clear from rofecoxib, which is more than 50-fold COX-2 selective. After looking at all above mentioned facts, natural product-based compounds seem better as these compounds are generally supposed to be devoid of severe side effects. The literature indicates that natural product-based compounds are mainly COX-1 selective. Through minor semisynthetic changes in the structures, their selectivity towards COX-2 can be increased. The present review article addresses natural product COX inhibitors of plant and marine origin, reported during last ten years and their advantages, possible leads for further development and current status. In addition we describe our experience in the characterization, design and synthesis of potential natural COX inhibitors.
Export Options
About this article
Cite this article as:
Jachak M. Sanjay, Cyclooxygenase Inhibitory Natural Products: Current Status, Current Medicinal Chemistry 2006; 13 (6) . https://dx.doi.org/10.2174/092986706776055698
DOI https://dx.doi.org/10.2174/092986706776055698 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computational Simulation of Drug Delivery at Molecular Level
Current Medicinal Chemistry Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Does Calprotectin Represent a Regulatory Factor in Host Defense or a Drug Target in Inflammatory Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids
Current Medicinal Chemistry Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Effect of Systemic Inflammation on the Function of Insulin and Glucose Metabolism in Rheumatoid Arthritis
Current Diabetes Reviews Molecular Phenotyping of Mouse Mutant Resources by RNA Expression Profiling
Current Genomics Airway Clearance of Apoptotic Cells in COPD
Current Drug Targets Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Current Pharmaceutical Design Orchestrating HIV Neutralization by Secondary Immune Response- Mediated Induction of RF Antibodies
Current Immunology Reviews (Discontinued) A Review of the Psychometric Properties and Use of the Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) in Clinical Research
Current Rheumatology Reviews The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid Arthritis
Current Pharmaceutical Design Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Small Molecule Immunosuppressive Agents in Experimental and Clinical Transplantation
Current Drug Targets - Cardiovascular & Hematological Disorders Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Mini-Reviews in Medicinal Chemistry Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Multicomponent Reactions for the Synthesis of Bioactive Compounds: A Review
Current Organic Synthesis Patent Annotations
Recent Patents on Anti-Infective Drug Discovery